Why did 4502.T rise 5.0%?

WDIV

TAKEDA PHARMACEUTICAL CO LTD · Health Care

Detected 16 Oct 2026, 9:00 am Sydney time

+4.99%2.1× normal volumeRegulatory

What moved it

Takeda Pharmaceutical (4502) surged ~5% driven by a combination of a successful Phase 3 psoriasis trial win, a subsequent analyst buy-rating reaffirmation, and a raised price target to JPY 5,800, all occurring in the days immediately preceding the move.

How we got there

The Nikkei 225 fell nearly 5% on the same day, making the ~5% up move in 4502 highly idiosyncratic and stock-specific rather than market-driven. News from October 13-15 consistently points to a Phase 3 psoriasis data win, a reaffirmed buy rating citing a drug approval catalyst, and a raised analyst price target to JPY 5,800 — a cluster of positive catalysts that credibly explains both the direction and the outsized magnitude (4.3x ATR). The 2.1x volume uplift is consistent with institutional accumulation following a clinical/regulatory catalyst rather than a broad macro or sector rotation.

The evidence

In the news

  • Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $20.74, Implies 9% Upside

    TradingView · 15 Oct 2026

  • Takeda Pharmaceutical : to Hold Earnings Call for Fiscal Year 2026 2nd Quarter on October 29

    www.marketscreener.com · 15 Oct 2026

  • Takeda Pharmaceutical stock trades at 52.50 times earnings

    ad-hoc-news.de · 15 Oct 2026

  • How Investors May Respond To Takeda (TSE:4502) Phase 3 Psoriasis Win

    Simply Wall Street · 14 Oct 2026

10 articles read; the newest from each outlet is shown. Headlines link to the publisher.

Markets that moved with it · 5

Markets that tend to move with this stock, on the same day or the day before.

  • GC=F+0.54%
  • Crude oil futures−0.39%
  • ^VIX−2.43%
  • Nikkei 225−4.90%
  • USDJPY=X−0.18%

What it did to the 44 ETFs holding 4502.T

Keep going

How is the site working for you?